Intravitreal Bevacizumab in Diabetic Retinopathy. Recommendations from the Pan-American Collaborative Retina Study Group (PACORES): The 2016 Knobloch Lecture

The advent of intravitreal anti-vascular endothelial growth factor (anti-VEGF) medications has revolutionized the treatment of diabetic eye diseases. Herein, we report the outcomes of clinical studies carried out by the Pan-American Collaborative Retina Study Group (PACORES), with a specific focus o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) Pa.), 2018-01, Vol.7 (1), p.36-39
Hauptverfasser:	Arevalo, J Fernando, Liu, T Y Alvin
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - therapeutic use Bevacizumab - administration & dosage Bevacizumab - therapeutic use Chemotherapy, Adjuvant Diabetic Retinopathy - drug therapy Humans Intravitreal Injections Macular Edema - drug therapy Preoperative Care
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The advent of intravitreal anti-vascular endothelial growth factor (anti-VEGF) medications has revolutionized the treatment of diabetic eye diseases. Herein, we report the outcomes of clinical studies carried out by the Pan-American Collaborative Retina Study Group (PACORES), with a specific focus on the efficacy of intravitreal bevacizumab in the management of diabetic macular edema and proliferative diabetic retinopathy. We will also discuss the use of intravitreal bevacizumab as a preoperative, adjuvant therapy before vitrectomy for proliferative diabetic retinopathy.
ISSN:	2162-0989
DOI:	10.22608/APO.2017466